Long-term dynamics of epidemiological characteristics of some chronic leukemia and lymphoma in Moscow before, during and after the pandemic of the new coronavirus infection COVID-19. Epidemiologic study

Cover Page

Cite item

Full Text

Abstract

Background. The COVID-19 pandemic, which swept the world in 2020–2021, had a significant impact on the epidemiological picture of hematological malignancies.

Aim. To study the dynamics of epidemiological indicators of five chronic hemoblastoses in Moscow over a 12-year period, and also to assess the impact of the COVID-19 pandemic on these indicators.

Materials and methods. A population-based study was conducted for five types of oncohematological diseases: multiple myeloma, Hodgkin's lymphoma, follicular lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia. The annual rates of morbidity, mortality, prevalence of these nosologies, overall survival, and expected overall survival were calculated. Gender and age characteristics for each disease were determined.

Results and discussion. The present study showed a uniform increase in the incidence and prevalence of five hematological malignancies between 2012 and 2019. Convincing evidence of an increase in mortality and a decrease in the number of diagnosed cases in comparison with the expected figures for these hematological malignancies in 2020–2021 was presented. A greater reduction was shown for cases diagnosed at early stages compared to later ones. During the pandemic, a significant increase in mortality was recorded among patients with chronic lymphocytic leukemia and multiple myeloma, while in cohorts of patients with chronic myeloid leukemia and Hodgkin lymphoma it increased slightly. The return of morbidity, mortality and prevalence rates to the original dynamics in 2022–2023 has been demonstrated.

Conclusion. This study demonstrated the features of the regional pattern of incidence, mortality, prevalence and gender-age characteristics of five hematological malignancies and provided the changes in the indicators dynamics of different hematological malignancies during the COVID-19 pandemic.

About the authors

Olga Yu. Vinogradova

Botkin Hospital; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University

Author for correspondence.
Email: olgavinz@mail.ru
ORCID iD: 0000-0002-3669-0141

D. Sci. (Med.), Botkin Hospital, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Pirogov Russian National Research Medical University

Russian Federation, Moscow; Moscow; Moscow

Mikhail V. Chernikov

Botkin Hospital

Email: mchernikov25@mail.ru
ORCID iD: 0000-0002-7869-209X

Res. Officer

Russian Federation, Moscow

Anna L. Neverova

Botkin Hospital

Email: anyuta6549@yandex.ru
ORCID iD: 0000-0001-9524-7070

Cand. Sci. (Biol.)

Russian Federation, Moscow

Victoria P. Kosenkova

Botkin Hospital

Email: kosenkowa.vik@yandex.ru
ORCID iD: 0009-0001-2974-4973

hematologist

Russian Federation, Moscow

Yulia B. Kochkareva

Botkin Hospital

Email: kochkareva_yulia@mail.ru

Cand. Sci. (Med.)

Russian Federation, Moscow

Dzhariiat I. Shikhbabaeva

Botkin Hospital

Email: djeri.shih@mail.ru
ORCID iD: 0000-0002-1384-1621

Cand. Sci. (Med.)

Russian Federation, Moscow

Maria M. Pankrashkina

Botkin Hospital

Email: bobkowa.hematol@mail.ru
ORCID iD: 0000-0002-5658-9729

Cand. Sci. (Med.)

Russian Federation, Moscow

Nikolai N. Sharkunov

Botkin Hospital

Email: anyuta6549@yandex.ru

hematologist

Russian Federation, Moscow

Vadim V. Ptushkin

Botkin Hospital; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University; Russian Medical Academy of Continuous Professional Education

Email: vadimvadim@inbox.ru
ORCID iD: 0000-0002-9368-6050

D. Sci. (Med.), Prof., Botkin Hospital, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Pirogov Russian National Research Medical University, Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow; Moscow; Moscow; Moscow

References

  1. Покровский В.И., Пак С.Г., Брико Н.И., Данилкин Б.К. Инфекционные болезни и эпидемиология: учебник. 2-е изд. М.: ГЭОТАР-Медиа, 2007 [Pokrovskii VI, Pak SG, Briko NI, Danilkin BK. Infektsionnye bolezni i epidemiologiia: uchebnik. 2-e izd. Moscow: GEOTAR-Media, 2007 (in Russian)].
  2. Макмахон Б., Трихопулос Д. Эпидемиология: принципы и методы. 2-е изд. Бостон: Литтл, Браун; 1996 [Makmakhon B, Trikhopulos D. Epidemiologia: printsipy i metody. 2-e izd. Boston: Littl, Braun; 1996 (in Russian)].
  3. Куликов С.М., Гармаева Т.Ц. Популяционные исследования в гематологии. Вестник последипломного медицинского образования. 2014;1:1-74 [Kulikov SM., Garmaieva TTs. Populiatsionnye issledovania v gematologii. Vestnik poslediplomnogo meditsinskogo obrazovaniia. 2014;1:1-74 (in Russian)].
  4. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi: 10.3322/caac.21834
  5. Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi: 10.1186/s13045-021-01177-0
  6. Чуднова Т.С., Мисюрина Е.Н., Барях Е.А., и др. COVID-19 у пациентов с острыми лейкозами: опыт 3 лет пандемии. Онкогематология. 2023;18(4):45-52 [Chudnova TS, Misiurina EN, Bariakh EA, et al. COVID-19 in patients with acute leukemia: 3 years’ experience of pandemic. Oncohematology. 18(4):45-52 (in Russian)]. doi: 10.17650/1818-8346-2023-18-4(Suppl)-45-52
  7. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. doi: 10.1182/blood-2016-03-643544
  8. Виноградова О.Ю., Птушкин В.В., Черников М.В., и др. Эпидемиология множественной миеломы в городе Москве. Терапевтический архив. 2019;91(7):83-92 [Vinogradova OYu, Ptushkin VV, Chernikov MV, et al. Epidemiology of multiple myeloma in city Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(7):83-9 (in Russian)]. doi: 10.26442/00403660.2019.07.000305
  9. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-34. doi: 10.1182/blood-2010-05-282632
  10. Blimark CH, Turesson I, Genell A, et al. Swedish Myeloma Registry. Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR). Haematologica. 2018;103(3):506-13. doi: 10.3324/haematol.2017.178103
  11. Chen Y, Wang H, Kantarjian H, et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54(7):1411-7. doi: 10.3109/10428194.2012.745525
  12. Rafiq M, Hayward A, Warren-Gash C, et al. Socioeconomic deprivation and regional variation in Hodgkin’s lymphoma incidence in the UK: a population-based cohort study of 10 million individuals. BMJ Open. 2019;9(9):e029228. doi: 10.1136/bmjopen-2019-029228
  13. Li Y, Wang Y, Wang Z, et al. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol. 2015;39(1):8-13. doi: 10.1016/j.canep.2014.12.001
  14. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41. doi: 10.3322/caac.21149
  15. Волкова С.А., Ковалишена О.В., Гостюжова Е.А., и др. Эффект от терапии иматинибом по данным клинико-эпидемиологического мониторинга хронического миелолейкоза в Нижегородской области за период 2000–2010 г. Гематология и трансфузиология. 2011;4:17-9 [Volkova SA, Kovalishena OV, Gostyuzhova EA, et al. Effekt ot terapii imatinibom po dannym kliniko-epidemiologicheskogo monitoringa khronicheskogo myeloleikoza v nizhegorodskoi oblasti za period 2000–2010 g. Gematologiia i transfuziologiia. 2011;4:17-9 (in Russian)].
  16. Лучинин А.С., Семочкин С.В., Минаева Н.В., и др. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области. Онкогематология. 2017;12(3):50-6 [Luchinin AS, Semochkin SV, Minaeva NV, et al. Epidemiology of multiple myeloma according to the Kirov region population registers. Oncohematology. 2017;12(3):50-6 (in Russian)]. doi: 10.17650/1818-8346-2017-12-3-50-56
  17. Войцеховский В.В., Ландышев Ю.С., Есенина Т.В., и др. Эпидемиология онкогематологических заболеваний в Амурской области. Амурский медицинский журнал. 2014;3(7):61-6 [Voytsehovskiy VV, Landyshev YuS, Esenina TV, et al. Epidemiology of hematologic malignancies in the Amur region. Amur Medical Journal. 2014;3(7):61-6 (in Russian)].
  18. Поспелова Т.И., Березина О.В., Ковынев И.Б., и др. Хронический лимфолейкоз в г. Новосибирске: реальная клиническая практика. Бюллетень медицинской науки. 2021;3(23):66-72 [Pospelova TI, Berezina OV, Kovynev IB, et al. Chronic lymphocytic leukemia: Novosibirsk real clinical practice. Bulletin of Medical Science. 2021;3(23):66-72 (in Russian)]. doi: 10.31684/25418475_2021_3_66
  19. Зверев А.М., Ружникова А.А., Левит М.Л., Бурдаева О.Н. Эпидемиология лимфомы Ходжкина и неходжкинских лимфом в Архангельской области за период с 2000 по 2009 г. Гематология и трансфузиология. 2014;59(1-S1):95 [Zverev AM, Ruzhnikova AA, Levit ML, Burdaeva ON. Epidemiologiya limfomy Hodzhkina i nekhodzhkinskih limfom v Arhangel'skoi oblasti za period s 2000 po 2009 g. Gematologiia i transfuziologiia. 2014;59(1-S1):95(in Russian)].
  20. Solovev MV, Mendeleeva LP, Pokrovskaya OS, et al. Epidemiology and Clinical Characteristics of Patients with Multiple Myeloma. Results of a Prospective Multicenter Study in Russian Federation. Blood. 2015;126:4248.
  21. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-32. doi: 10.3322/caac.21438
  22. Junlén HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668-76. doi: 10.1038/leu.2014.251
  23. Куликов С.М., Виноградова О.Ю., Челышева Е.Ю., и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009-2012 гг. Терапевтический архив. 2014;86(7):24-30 [Kulikov SM, Vinogradova OIu, Chelysheva EIu, et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study. Terapevticheskii Arkhiv (Ter. Arkh.). 2014;86(7):2430 (in Russian)].
  24. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25-35. doi: 10.1007/978-3-540-85772-3_2
  25. Multiple myeloma epidemiology and demographics Ed. CM Gibson, H Allaham. 2018.
  26. National cancer institute (2015). Available at: http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#cit/section_1.1. Accessed: 20.09.2015.
  27. Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336-43. doi: 10.1038/leu.2015.73
  28. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74. doi: 10.1038/s41408-020-00340-z
  29. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
  30. Витрина статистических данных. Численность постоянного населения. Режим доступа: https://showdata.gks.ru/report/278928/ Ссылка активна на 12.01.2024 [Showcase of statistical data. Resident population. Available at: https://showdata.gks.ru/report/278928/ Accessed: 12.01.2024 (in Russian)].
  31. Бутуханова И.С., Жалсанова Э.Б., Алексеева А.Н., и др. Анализ заболеваемости множественной миеломой в Республике Бурятия. Современные проблемы науки и образования. 2016;4 [Butukhanova IS, Zhalsanova EB, Alekseyeva AN, et al. Analiz zabolevaiemosti mnozhestvennoi mielomoi v Respublike Buriatiia. Sovremennyie problemy nauki i obrazovaniia. 2016;4 (in Russian)].
  32. National Cancer Institute Surveillanse, Epidemiology, and End Results. Cancer Stat Facts: Leukemia- Chronic Lymphocytic Leukemia (CLL). Available at: https://seer.cancer.gov/statfacts/html/clyl.html.2020. Accessed: 14.12.2023.
  33. Cerhan JR. Epidemiology of Follicular Lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631-46. doi: 10.1016/j.hoc.2020.02.001
  34. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-59. doi: 10.3322/caac.21357
  35. Sasaki K, Haddad FG, Short NJ, et al. Outcome of Philadelphia chromosome-posi- tive chronic myeloid leukemia in the United States since the introduction of imatinib therapy – The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023;129(23):3805-14. doi: 10.1002/cncr.35038
  36. Negoita S, Chen HS, Sanchez PV, et al. Annual Report to the Nation on the Status of Cancer, part 2: Early assessment of the COVID-19 pandemic’s impact on cancer diagnosis. Cancer. 2024;130(1):117-27. doi: 10.1002/cncr.35026
  37. El-Ashwah S, Salmanton-García J, Bilgin YM, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2024;65(2):199-208. doi: 10.1080/10428194.2023.2280886
  38. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-92. doi: 10.1182/blood.2020008824
  39. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-43. doi: 10.1182/blood.2020006965
  40. Galimberti S, Petrini M, Baratè C, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol. 2020;10:1428. doi: 10.3389/fonc.2020.01428

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Epidemiological indicators of multiple myeloma (MM): a – dynamics of recorded prevalence, incidence, mortality in the region in 2012–2023; b – gender and age characteristics of patients; c – indicators of overall servival (OS) of patients with MM in general and gender groups and time expected survival.

Download (369KB)
Indexing metadata
3. Fig. 2. Dynamics of the number of registered in the region in 2019–2021: a – new cases of MM; b – deaths among patients with MM.

Download (154KB)
Indexing metadata
4. Fig. 3. Epidemiological indicators of chronic lymphocytic leukemia (CLL): a – dynamics of recorded prevalence, incidence, mortality in the region in 2012–2023; b – gender and age characteristics of patients; c – indicators of OS of patients with CLL in general and gender groups and time expected survival.

Download (342KB)
Indexing metadata
5. Fig. 4. Dynamics of the number of registered in the region in 2019–2021: a – new cases of CLL; b – deaths among patients with CLL.

Download (169KB)
Indexing metadata
6. Fig. 5. Epidemiological indicators of follicular lymphoma (FL): a – dynamics of recorded prevalence, incidence, mortality in the region in 2012–2023; b – gender and age characteristics of patients; c – indicators of OS of patients with FL in general and gender groups and time expected survival.

Download (362KB)
Indexing metadata
7. Fig. 6. Epidemiological indicators of Hodgkin lymphoma (HL): a – dynamics of recorded prevalence, incidence, mortality in the region in 2012–2023; b – gender and age characteristics of patients; c – indicators of OS of patients with HL in general and gender groups and time expected survival.

Download (340KB)
Indexing metadata
8. Fig. 7. Epidemiological indicators of chronic myeloid leukemia (CML): a – dynamics of recorded prevalence, incidence, mortality in the region in 2012–2023; b – gender and age characteristics of patients; c – indicators of OS of patients with CML in general and gender groups and time expected survival.

Download (359KB)
Indexing metadata

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies